NanoViricides Anticipates FluCide™ Drug Candidates to be Effective Against H7N9
Tuesday, April 23, 2013
NanoViricides, Inc. anticipates that the oral and injectable FluCide™ drug candidates would be effective against the novel H7N9 strain that has caused human fatalities in China in recent months.
Haselmeier Establishes Haselmeier Inc. in the United States
Tuesday, April 23, 2013
Haselmeier announced that it has established a new company in the United States, Haselmeier Inc., a fully owned subsidiary of Haselmeier GmbH.
BioAlliance Pharma’s Sitavig® Receives Market Authorization in the US
Tuesday, April 16, 2013
Authorization from the U.S. FDA for Sitavig® in the treatment of recurring Herpes labialis, marking the successful conclusion to the assessment procedure carried out by the American authorities.
Side Effects to be Discovered more Quickly, Leading to Safer Prescribing
Monday, April 15, 2013
BMJ Learning has teamed up with the MHRA to launch a new, interactive and multimedia learning module on pharmacovigilance.
Researchers Discover New Therapy for Fragile X Chromosome Syndrome
Monday, April 15, 2013
Researchers at the University of the Basque Country (UPV/EHU) and the Achucarro neurosciences centre have discovered a new therapy for the fragile X chromosome syndrome.
Thermo Fisher Scientific to Acquire Life Technologies Corporation
Monday, April 15, 2013
The definitive agreement will see Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share or approximately $13.6 billion.
Promega and BASF Develop Alternative Method on Identifying Allergenic Substances
Thursday, April 11, 2013
Animal studies for cosmetic starting materials completely prohibited in the EU since March.
Onconova Announces Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer
Wednesday, April 10, 2013
Oral rigosertib progresses to phase 2 clinical trial in squamous cell head and neck cancers.
Roche and Isis Pharmaceuticals Form Alliance for Huntington's Disease
Wednesday, April 10, 2013
This alliance combines Isis' antisense expertise with Roche's scientific expertise in developing neurodegenerative therapeutics.
|
|
|
| << | 1 2 3 4 5 6 7 | >> | | Showing Results 21 - 30 of 2169 |
|
|
